Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy

NCT02574637 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02574637
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02574637 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Terminated
Start date
January 5, 2016
Completion date
January 29, 2018
Enrollment
29 (actual)
Sites
97

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease